View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
June 4, 2020

Memo Therapeutics discovers neutralising antibodies against Covid-19

Switzerland-based Memo Therapeutics has discovered multiple SARS-CoV-2 neutralising antibodies with the potential for development as immunotherapy against Covid-19.

Switzerland-based Memo Therapeutics has discovered multiple SARS-CoV-2 neutralising antibodies with the potential for development as immunotherapy against Covid-19.

Since March, the company has selected certain donors from Covid-19 patients in the country. The selection criteria was for patients who had a clinical course of the disease indicative of a potent antibody response.

Memo Therapeutics collected blood samples from the selected donors and used its microfluidic DROPZYLLA discovery platform to find virus-neutralising antibodies.

The platform is designed to allow the production of complete recombinant human antibody repertoires. It is said to preserve all characteristics present in each patient’s B cells.

Memo Therapeutics CEO Dr Karsten Fischer said: “The identification of SARS-CoV-2-neutralizing antibodies could be a game-changer in how we tackle the global Covid-19 pandemic.

“The discovery process and ongoing clinical development may also provide key insights into how we can combat new mutants and viral outbreaks in the future, as well as other existing viral diseases.”

The company processed more than two million memory B-cells from Covid-19 donors and identified ultra-rare antibodies with promising virus-neutralising activity.

Among these antibodies, the most potent will advance into clinical development as passive immunotherapy for Covid-19. A clinical proof-of-concept could be conducted in the fourth quarter of this year.

Memo Therapeutics CSO Dr Christoph Esslinger said: “We are also extremely pleased to see that our DROPZYLLA antibody discovery platform and the established workflow appear to be perfectly suited for a rapid pandemic response, and we believe that patient-derived antibodies are the most straightforward, safe and reliable therapeutic option for such a situation.”

The company is currently working on infectious diseases and immuno-oncology programmes.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology